Merck マネジメント

マネジメント基準チェック /34

Merckの CEO はRob Davisで、 Apr2021年に任命され、の在任期間は 4.17年です。の年間総報酬は$ 23.19Mで、 7%給与と93%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.018%を直接所有しており、その価値は€ 29.99M 。経営陣と取締役会の平均在任期間はそれぞれ4.4年と5.8年です。

主要情報

Rob Davis

最高経営責任者

US$23.2m

報酬総額

CEO給与比率	7.00%
CEO在任期間	4.2yrs
CEOの所有権	0.02%
経営陣の平均在職期間	4.4yrs
取締役会の平均在任期間	5.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Merck の収益と比較して、Rob Davis の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2025	n/a	n/a	US$17b
Dec 31 2024	US$23m	US$2m	US$17b
Sep 30 2024	n/a	n/a	US$12b
Jun 30 2024	n/a	n/a	US$14b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$20m	US$2m	US$365m
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$13b
Dec 31 2022	US$19m	US$2m	US$15b
Sep 30 2022	n/a	n/a	US$15b
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b
Sep 30 2019	n/a	n/a	US$9b
Jun 30 2019	n/a	n/a	US$9b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$7m	US$1m	US$6b

報酬と市場: Robの総報酬 ($USD 23.19M ) は、 German市場 ($USD 5.26M ) の同規模の企業の平均を上回っています。

報酬と収益: Robの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Rob Davis (58 yo)

4.2yrs

在職期間

US$23,186,065

報酬

Mr. Robert M. Davis, also known as Rob, J. D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December 01, 2022. He serves as President at Merck & Co.,...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Davis	Chairman	4.2yrs	US$23.19m	0.018% € 30.0m
Caroline Litchfield	Executive VP & CFO	4.2yrs	US$7.51m	0.0030% € 5.0m
Betty Larson	Executive VP & Chief Human Resources Officer	1.2yrs	US$11.26m	0.00025% € 424.3k
Richard DeLuca	Executive VP & President of Merck Animal Health	13.8yrs	US$9.10m	0.0073% € 12.3m
Dean Li	Executive VP & President of Merck Research Laboratories	7.6yrs	US$10.09m	0.0032% € 5.4m
Dalton Smart	Senior VP of Finance	1.5yrs	データなし	0.00038% € 644.9k
David Williams	Executive VP and Chief Information & Digital Officer	no data	データなし	0.00096% € 1.6m
Peter Dannenbaum	Vice President of Investor Relations	5.8yrs	データなし	データなし
Jennifer Zachary	Executive VP & General Counsel	7.2yrs	US$5.90m	0.0022% € 3.8m
Cristal Downing	Executive VP and Chief Communications & Public Affairs Officer	3.8yrs	データなし	0.00028% € 475.2k
Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	15.6yrs	US$6.24m	0.0074% € 12.5m
Johannes Oosthuizen	Senior VP & President Merck U.S. Human Health	4.4yrs	データなし	0.0012% € 2.1m

4.4yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: 6MKの経営陣は経験豊富であると考えられます ( 4.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Davis	Chairman	3.9yrs	US$23.19m	0.018% € 30.0m
Pamela Craig	Independent Director	9.8yrs	US$403.75k	0.000070% € 118.8k
Patricia Russo	Independent Director	29.8yrs	US$363.75k	0.00052% € 882.5k
Thomas Glocer	Independent Lead Director	17.6yrs	US$436.25k	0.00020% € 339.4k
Risa Lavizzo-Mourey	Independent Director	5.1yrs	US$361.00k	0.000040% € 67.9k
Douglas Baker	Independent Director	3.1yrs	US$350.00k	0.00064% € 1.1m
Inge Thulin	Independent Director	7.3yrs	US$340.00k	0.00012% € 203.7k
Stephen Mayo	Independent Director	4.3yrs	US$350.00k	0% € 0
Kathy Warden	Independent Director	5.3yrs	US$350.00k	0.000020% € 33.9k
Christine Seidman	Independent Director	5.3yrs	US$375.00k	0% € 0
Paul Rothman	Independent Director	9.8yrs	US$413.75k	0% € 0
Mary Coe	Independent Director	6.3yrs	US$340.00k	0% € 0

5.8yrs

平均在職期間

66.5yo

平均年齢

経験豊富なボード: 6MKの取締役会は経験豊富であると考えられます ( 5.8年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/06/04 14:29
終値	2025/06/04 00:00
収益	2025/03/31
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Merck & Co., Inc. 26 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。57

アナリスト	機関
David Toung	Argus Research Company
Fabrizio Spagna	Axia Financial Research
Charles Butler	Barclays

Merck マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Merck & Co., Inc., Annual General Meeting, May 27, 2025

Independent Director recently bought €1.3m worth of stock

Merck & Co., Inc. Appoints Surendralal L. Karsanbha to its Board of Directors, Effective January 1, 2025

Recent updates

Merck Reportedly Held Talks to Buy MoonLake for over $3B

First quarter dividend of US$0.81 announced

Merck's Investigational Zilovertamab Vedotin at 1.75 mg/Kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients with Relapsed/Refractory DLBCL in Phase 2 Portion of Waveline-003 Trial

Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw

Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2025, Payable on July 8, 2025

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival in Patients with Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers

Research on Novel Treatment Approaches and Scientific Advances from Merck's Broad and Differentiated Oncology Portfolio and Pipeline to Be Presented at ASCO 2025

Dawn Health and Merck Launch Next-Generation Digital Ecosystem for Growth Disorders

New minor risk - Insider selling

Merck Announces Results from the Phase 3 KEYNOTE-689 Trial Evaluating KEYTRUDA

First quarter 2025 earnings released: EPS: US$2.01 (vs US$1.88 in 1Q 2024)

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Merck & Co., Inc., Annual General Meeting, May 27, 2025

Merck Announces First Presentation of Results from the Phase 3 Zenith Trial Evaluating Winrevair™

Merck & Co., Inc.'s Investigational Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Demonstrates Noninferior Pharmaceuticaletics Compared to Intravenous (IV) KEYTRUDA®? (Pembrolizumab) in Pivotal 3475A-D77 Trial

European Commission Approves Merck's Capvaxive®? (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Merck Data At Acc.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease

Merck Announces Positive Data from Phase 3 Trials That Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravir/Islatravir Maintained HIV-1 Viral Suppression At Week 48

Upcoming dividend of US$0.81 per share

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Merck Receives First European Commission Approval for Two Indications

Health Canada Approves Merck's KEYTRUDA® (Pembrolizumab) for the Treatment of Adult Patients with Respirable Non-Small Cell Lung Cancer

Independent Director recently bought €1.3m worth of stock

Merck Announces Phase 3 Waveline-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Full year 2024 earnings released: EPS: US$6.74 (vs US$0.14 in FY 2023)

Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2025

Third quarter dividend of US$0.81 announced

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis

Merck Announces Second-Quarter 2025 Dividend, Payable on April 7, 2025

FDA Grants Priority Review to Merck's Application for WELIREG (belzutifan) for the Treatment of Patients with Advanced Pheochromocytoma and Paraganglioma (PPGL)

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvima) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

Merck’s GARDASIL® Receives Expanded Approval for Males in China

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

Merck & Co., Inc. Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab

Merck Receives Positive EU CHMP Opinion for WELIREG®? (belzutifan) as Treatment for Adult Patients with Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients with Advanced Renal Cell Carcinoma

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer

Merck & Co., Inc. Announces First Presentation of Data from the Phase 2 Waveline-007 Trial Evaluating Zilovertamab Vedotin

Merck & Co., Inc. Announces Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIOTM (Molnupiravir) for the Treatment of Covid-19 in High-Risk Adults

Merck's Sacituzumab Tirumotecan Granted FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Merck Announces Pivotal Phase 3 Zenith Trial Evaluating Winrevair Met Primary Endpoint At Interim Analysis

Third quarter dividend of US$0.81 announced

Merck & Co., Inc. Appoints Surendralal L. Karsanbha to its Board of Directors, Effective January 1, 2025

Merck & Co., Inc.'s WELIREG (Belzutifan) Approves in China for the Treatment of Adult Patients with Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Met Primary Endpoints

Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

Third quarter 2024 earnings released: EPS: US$1.24 (vs US$1.87 in 3Q 2023)

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck and Moderna Initiates INTerpath-002, A Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda® (Pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer

Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma

Miller Law LLC and Motley Rice LLC Announce a Proposed Settlement in re Zetia (Ezetimibe) Antitrust Litigation

Merck & Co., Inc. (NYSE:MRK) completed the acquisition of Prometheus Biosciences, Inc. (NasdaqGS:RXDX) from a group of shareholders.

U.S. FDA Approves New Indication for Merck's PREVYMIS®? (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

マネジメント基準チェック /34